Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T12:50:20.187Z.
Calculation as of: 2026-10-06T12:50:20.187Z.
Quote observation: 2026-10-05T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fa223cd5a0006a47bd3f11d3634c651a1c818c2f8beb58cb941cded2cdd6eca8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$11.01M
PS Ratio
36.86
TTM Avg
104.45
3Y Avg
295.11
5Y Avg
603.14
Market Cap
$11.95M
PS Ratio
N/A
TTM Avg
32.91
3Y Avg
62.07
5Y Avg
66.46
Market Cap
$10.27M
PS Ratio
8856.38
TTM Avg
9868.69
3Y Avg
9868.69
5Y Avg
9868.69
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.42M | N/A | N/A | N/A | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.41M | 0.25 | 0.28 | 0.18 | 0.48 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | 36.86 | 104.45 | 295.11 | 603.14 |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | 32.91 | 62.07 | 66.46 |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.74M | 2.55 | 4.41 | 4.41 | 4.41 |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | 0.33 | 0.98 | 1.40 | 2.22 |
| Caring Brands, Inc. (CABR)vs › | $10.27M | 8856.38 | 9868.69 | 9868.69 | 9868.69 |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | 9.25 | 21.58 | 247.97 | 174.73 |
| SeaStar Medical Holding Corporation (ICU)vs › | $10.07M | 5.88 | 39.64 | 50.81 | 50.81 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-05 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
